GFAP and androgen insensitivity syndrome: Previous studies have already shown a positive correlation of these biomarkers in blood with the functional outcome and the extent of tissue damage and the feasibility (for GFAP when performed in the early phase) to even differentiate between etiologies (ICH vs. AIS)6,8–10.